ABBVAbbVieRunning, no new patients
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
Acute Myeloid Leukemia (AML)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 443 (final count)
- Started
- Feb 2, 2017
- Main results expected
- Dec 1, 2021
- Fully finished
- Jun 15, 2026
- Results posted
- Jan 27, 2023
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021)
Percentage of Participants With Complete Remission (CR) and Complete Remission With Incomplete Marrow Recovery (CRi)
Measured over: From the study start up to death (up to approximately 4.8 years; data cut-off date: 1 December 2021)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02993523 · record last updated 2026-06-11 · checked 2026-11-09 15:47 UTC